Insmed reports first quarter 2022 financial results and provides business update

--arikayce® (amikacin liposome inhalation suspension) achieves 32% year over year growth for the first quarter of 2022 with total revenue of $53.1 million-- --seven clinical trials underway; enrollment on track in brensocatib phase 3 aspen study and arikayce post-marketing studies (arise and encore)-- --company reiterates revenue guidance of at least 30% growth in 2022 and cash runway into 2024 to support ongoing programs-- bridgewater, n.j. , may 5, 2022 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended march 31, 2022 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking